Market/Novel Tech

Editas Medicine, Inc. (NASDAQ; EDIT) has announced positive clinical data on their CRISPR gene therapy product on LCA10

Editas Medicine, Inc. (NASDAQ: EDIT) has announced positive initial clinical data from an ongoing, open label Phase I/II “BRILLIANCE” study EDIT-101, a CRISPR-based experimental treatment… Read More »Editas Medicine, Inc. (NASDAQ; EDIT) has announced positive clinical data on their CRISPR gene therapy product on LCA10

Novartis Institutes for BioMedical Research (NIBR) announces the acquisition of Arctos Medical on optogenetics treatments

Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary… Read More »Novartis Institutes for BioMedical Research (NIBR) announces the acquisition of Arctos Medical on optogenetics treatments

GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France

GenSight Biologics (Euronext: SIGHT), announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament… Read More »GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France